About Regeneron Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.regeneron.com/
Frequently Asked Questions
What is the 52-week range for REGN?
The 52-week high is $859.34 and the 52-week low is $541.
What is the P/E ratio for REGN?
The Price to Earnings (P/E) ratio is 17.41.
What is the dividend yield for REGN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 13.81%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 27.86%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.60.
Analyst Recommendation Trends
Wall Street analyst consensus for REGN over the last few months:
Latest REGN News
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.
An $8 Billion Reason Why Regeneron Stock Is in Focus
Regeneron announces an expanded deal with Sanofi. Here’s what the disclosure really means for REGN shares.
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
Sanofi pays Regeneron up to $8B to expand immunology alliance
Regeneron will receive $1 billion upfront, with up to $7 billion more in milestones, to co-develop four next-generation antibody drug candidates
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select biotechnology stocks with more reasonable finances can draw interest. This article breaks down three biotech stocks from a curated screener that aims to balance high upside with some measure of financial discipline. The stocks covered below are just a small...
Why Regeneron (REGN) Stock Is Trading Lower Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology alliance with Sanofi on terms that left economics for its blockbuster drug Dupixent untouched.
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs.
Which S&P500 stocks are moving on Thursday?
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies October 1, 2026 8:00 AM...
Sanofi, Regeneron broaden alliance to find their next Dupixent
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free survival in 11 patients with recurrent and heavily pre-treated LGSOC treated with the highest dose of ubamatamab in the trial Regeneron has been enrolling a dedicated LGSOC cohort at this dose and will ad
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and is in press with The Lancet TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharm
Pfizer’s eczema drug clears skin in mid-stage trial
Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framew
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
Kodiak Sciences reported strong endpoint results for its late-stage eye injection candidate, sending its stock soaring.
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930
Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT. Under the agreement, Regeneron will contribute four long-acting, fully hu
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion
Regeneron and Sanofi expand antibody pact targeting IL-4/IL-13 inflammation therapies, with $1B upfront and up to $7B milestones. Click to read my analysis for more.
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.
Regeneron Pharmaceuticals Announces Its Results From Phase 2 COURAGE Study Of Trevogrumab Shows 70% Prevention Of Muscle Loss Associated With Semaglutide Treatment; Lower Dose Of Trevogrumab Did Not Enhance Weight Loss Achieved With Semaglutide Alone
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and muscle loss during
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights
Sanofi and Regeneron are broadening their immunology pipeline while keeping their existing Dupixent economics intact.
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
Regeneron and Sanofi expand their 20-year antibody collaboration with a $1 billion upfront payment and new clinical trials.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - Slideshow
2026-10-01. The following slide deck was published by Regeneron Pharmaceuticals, Inc.
Regeneron Exec Says Co. Eligible To Receive $1B In Potential Milestone Payment With Start Of First Late-Stage Trial As Part Of Deal
https://edge.media-server.com/mmc/p/dfer26i6/
Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target
Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
Sanofi, Regeneron expand partnership in deal worth up to $8 billion
Investing.com -- Sanofi SA (EPA:SASY) will pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four new long-acting medicines for inflammatory diseases, as the French drugmaker looks to build its pipeline beyond its blockbuster Dupixent treatment.
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from RegeneronRegeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share dev
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Regeneron and Sanofi to host a conference
Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical
Why Moderna (MRNA) Shares Are Falling Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels.
This Analyst Just Downgraded Moderna Stock. Here's Why.
Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares today.
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum
Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.
REGN or ILMN: Which Is the Better Value Stock Right Now?
REGN vs. ILMN: Which Stock Is the Better Value Option?
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
BioFuture 2026 Convenes Industry Leaders in New York City to Explore the Trends Reshaping Biopharma and Healthcare
Demy-Colton today announced the agenda for BioFuture™ 2026, taking place October 27–28 at Cure, 345 Park Avenue South in New York City. The conference will bring together leaders from across biopharma, healthcare, investment, technology and policy for discussions, company presentations, networking and one-to-one partnering, followed by virtual partnering November 3–5.
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.
Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?
Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...
RBC Capital Reiterates Sector Perform on Regeneron Pharmaceuticals, Maintains $737 Price Target
RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and maintains $737 price target.
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?
Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...
New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs
Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
The healthcare company will release its third-quarter results next month.
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 172%
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Kodiak skyrockets on positive study data for 2 eye drugs
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
Kodiak’s stock rallies on Phase III wAMD success
If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Kodiak Sciences Stock Surges 156% After Eye-Disease Drugs Pass Key Trial
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Why This Regeneron Eye Rival Just Catapulted More Than 120%
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.
Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.
Kodiak Sciences Stock Pops 70% After Eye-Disease Drugs Pass Key Trial
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, have been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 202
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call InformationParticipants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s websi
Regeneron (REGN) Stock Still Looks Undervalued After A 40% Run
Regeneron Pharmaceuticals has delivered a strong share price run over the past year, which puts a spotlight on whether the current US$801.82 level is still grounded in what the business earns today. With the focus squarely on profits and the P/E discussion around them, the question is how much of that recent strength can be explained by earnings power rather than sentiment alone. The stock has returned 39.7% over the past year. This puts real pressure on the valuation case to be supported by...
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch. Chris Fenimore, Regeneron’s executive vice
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 10:30 AM...
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.
Is Regeneron Stock a Bargain Below $800?
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron Pharmaceuticals has a market
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine
Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event. Quigley said Chief Executive Offic
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care. Speaking at a Morgan Stanley fireside ch
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV delivery systems, precision medicine investment, and expanding clinical pipelines for genetic disorders, oncology, cardiovascular and neurological diseases. North America leads the market, while Asia-Pacific is expected to grow fastest. Key players include CRISPR Therapeut
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
Until 2007, paroxysmal nocturnal hemoglobinuria (PNH) was a life-threatening disorder with limited therapeutic options for controlling hemolysis and thrombosis, the latter being a major contributor to mortality. The treatment landscape underwent a significant transformation with the introduction of the anti-C5 complement inhibitor eculizumab, which substantially reduced hemolysis, lowered transfusion requirements, and, importantly, decreased the risk of thrombosis.
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.
Why This Biotech Stock Just Got a Rare Double Upgrade
The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.
Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative?
In September 2026, several law firms, including Bronstein, Gewirtz & Grossman and Robbins Geller Rudman & Dowd, filed federal securities class action lawsuits against Regeneron Pharmaceuticals, alleging that management misled investors about key design assumptions and clinical prospects for its Phase III Fianlimab-Libtayo oncology trial. The complaints center on claims that Regeneron understated the risk that Fianlimab-Libtayo would fail to show meaningful benefit over standard therapies,...
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Regeneron Pharmaceuticals (REGN) Could Be 5% Undervalued Following Trial Lawsuit News
Regeneron Pharmaceuticals (REGN) is back in focus after law firm Bronstein, Gewirtz & Grossman announced a securities class action tied to disclosures around the Phase III Fianlimab Libtayo trial. Recent trading tells a mixed story for Regeneron Pharmaceuticals. The share price is up 29.12% over the past 90 days and the 1 year total shareholder return is 39.33%, even though the 7 day share price return is down 4.11% as investors weigh the lawsuit headlines against a longer trend of positive...
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference. Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:05 PM EDTCompany ParticipantsRyan Crowe...
Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
DelveInsight's Bispecifics Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis, Systemic Lupus Erythema
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance. Ryan Crowe, senior vice president of investor relations and strategic ana
HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920
HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)
American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount
Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock
Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The letter can be downloaded here. Global equities experienced a sharp rally in Q2 2026, with the S&P 500 returning 15.2%, its strongest quarter since 2020, driven by a shift from software to hardware in the Artificial Intelligence […]
Big Short Billionaire Goes Long: Michael Burry Avoids AI, Bets on Beaten own Stocks Instead
While Wall Street piles into AI darlings, Michael Burry is quietly loading up on call options in three stocks the market left for dead, and his biggest bets carry a very specific thesis about where the crowd got it wrong.
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that period. This may have investors wondering how to approach the situation.
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
They could both outperform the market over the medium term, but one appears to have a clear edge.
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-03 | McCourt Marion | -1,131 | $857.39 | $969,708 |
| 2026-09-02 | Guarini Kathryn | -400 | - | - |
| 2026-09-02 | Guarini Kathryn | -400 | $850 | $340,000 |
| 2026-09-02 | Guarini Kathryn | +400 | $719.37 | $287,748 |
| 2026-09-02 | McCourt Marion | -1,215 | $850 | $1,032,750 |
| 2026-08-19 | LAROSA JOSEPH J | -12,282 | - | - |
| 2026-08-19 | LAROSA JOSEPH J | -9,019 | $830.15 | $7,487,123 |
| 2026-08-19 | LAROSA JOSEPH J | +12,282 | $381.92 | $4,690,741 |
| 2026-08-18 | Fenimore Christopher R. | -6,283 | - | - |
| 2026-08-18 | Fenimore Christopher R. | -4,599 | $813.47 | $3,741,149 |
| 2026-08-18 | Fenimore Christopher R. | +6,283 | $381.92 | $2,399,603 |
| 2026-08-10 | Guarini Kathryn | -400 | - | - |
| 2026-08-10 | Guarini Kathryn | -400 | $800 | $320,000 |
| 2026-08-10 | Guarini Kathryn | +400 | $719.37 | $287,748 |
| 2026-08-10 | Zoghbi Huda Y | -800 | - | - |
| 2026-08-10 | Zoghbi Huda Y | -800 | $800 | $640,000 |
| 2026-08-10 | Zoghbi Huda Y | +800 | $376.69 | $301,352 |
| 2026-07-02 | RYAN ARTHUR F | -200 | $650.15 | $130,030 |
| 2026-05-01 | RYAN ARTHUR F | -2 | $714.13 | $1,428 |
| 2026-05-01 | RYAN ARTHUR F | -1 | $712.09 | $712 |
| 2026-05-01 | RYAN ARTHUR F | -5 | $711.49 | $3,557 |
| 2026-05-01 | RYAN ARTHUR F | -2 | $710.87 | $1,422 |
| 2026-05-01 | RYAN ARTHUR F | -6 | $709.45 | $4,257 |
| 2026-05-01 | RYAN ARTHUR F | -4 | $707.4 | $2,830 |
| 2026-05-01 | RYAN ARTHUR F | -7 | $706.74 | $4,947 |
| 2026-05-01 | RYAN ARTHUR F | -14 | $705.56 | $9,878 |
| 2026-05-01 | RYAN ARTHUR F | -15 | $704.28 | $10,564 |
| 2026-05-01 | RYAN ARTHUR F | -24 | $703.46 | $16,883 |
| 2026-05-01 | RYAN ARTHUR F | -15 | $702.46 | $10,537 |
| 2026-05-01 | RYAN ARTHUR F | -5 | $701.76 | $3,509 |
| 2026-04-01 | RYAN ARTHUR F | -40 | $779.71 | $31,188 |
| 2026-04-01 | RYAN ARTHUR F | -4 | $778.24 | $3,113 |
| 2026-04-01 | RYAN ARTHUR F | -9 | $777.42 | $6,997 |
| 2026-04-01 | RYAN ARTHUR F | -13 | $776.62 | $10,096 |
| 2026-04-01 | RYAN ARTHUR F | -14 | $775.58 | $10,858 |
| 2026-04-01 | RYAN ARTHUR F | -8 | $774.58 | $6,197 |
| 2026-04-01 | RYAN ARTHUR F | -8 | $773.59 | $6,189 |
| 2026-04-01 | RYAN ARTHUR F | -3 | $772.76 | $2,318 |
| 2026-04-01 | RYAN ARTHUR F | -1 | $771.32 | $771 |
| 2026-03-02 | RYAN ARTHUR F | -20 | $789.28 | $15,786 |
| 2026-03-02 | RYAN ARTHUR F | -20 | $788.96 | $15,779 |
| 2026-03-02 | RYAN ARTHUR F | -2 | $787.34 | $1,575 |
| 2026-03-02 | RYAN ARTHUR F | -7 | $786.61 | $5,506 |
| 2026-03-02 | RYAN ARTHUR F | -11 | $785.48 | $8,640 |
| 2026-03-02 | RYAN ARTHUR F | -9 | $784.48 | $7,060 |
| 2026-03-02 | RYAN ARTHUR F | -10 | $783.62 | $7,836 |
| 2026-03-02 | RYAN ARTHUR F | -2 | $782.62 | $1,565 |
| 2026-03-02 | RYAN ARTHUR F | -2 | $781.21 | $1,562 |
| 2026-03-02 | RYAN ARTHUR F | -3 | $780.69 | $2,342 |
| 2026-03-02 | RYAN ARTHUR F | -5 | $779.69 | $3,898 |
| 2026-03-02 | RYAN ARTHUR F | -2 | $778.3 | $1,557 |
| 2026-03-02 | RYAN ARTHUR F | -7 | $777.46 | $5,442 |
| 2026-02-19 | Zoghbi Huda Y | -1,638 | - | - |
| 2026-02-19 | Zoghbi Huda Y | -4 | $790 | $3,160 |
| 2026-02-19 | Zoghbi Huda Y | -56 | $785.61 | $43,994 |
| 2026-02-19 | Zoghbi Huda Y | -160 | $784.45 | $125,512 |
| 2026-02-19 | Zoghbi Huda Y | -220 | $783.29 | $172,324 |
| 2026-02-19 | Zoghbi Huda Y | -298 | $782.1 | $233,066 |
| 2026-02-19 | Zoghbi Huda Y | -209 | $781.28 | $163,288 |
| 2026-02-19 | Zoghbi Huda Y | -331 | $780.45 | $258,329 |
| 2026-02-19 | Zoghbi Huda Y | -208 | $779.55 | $162,146 |
| 2026-02-19 | Zoghbi Huda Y | -53 | $778.47 | $41,259 |
| 2026-02-19 | Zoghbi Huda Y | -50 | $775.5 | $38,775 |
| 2026-02-19 | Zoghbi Huda Y | -49 | $774.68 | $37,959 |
| 2026-02-19 | Zoghbi Huda Y | +1,638 | $376.69 | $617,018 |
| 2026-02-09 | Pitofsky Jason | -1,000 | - | - |
| 2026-02-09 | Pitofsky Jason | -53 | $785.72 | $41,643 |
| 2026-02-09 | Pitofsky Jason | -1 | $784.66 | $785 |
| 2026-02-09 | Pitofsky Jason | -144 | $783.23 | $112,785 |
| 2026-02-09 | Pitofsky Jason | -37 | $782.67 | $28,959 |
| 2026-02-09 | Pitofsky Jason | -26 | $781.37 | $20,316 |
| 2026-02-09 | Pitofsky Jason | -75 | $780.06 | $58,504 |
| 2026-02-09 | Pitofsky Jason | -205 | $779.56 | $159,810 |
| 2026-02-09 | Pitofsky Jason | -563 | $778.35 | $438,211 |
| 2026-02-09 | Pitofsky Jason | -391 | $777.51 | $304,006 |
| 2026-02-09 | Pitofsky Jason | -521 | $776.43 | $404,520 |
| 2026-02-09 | Pitofsky Jason | -20 | $775.95 | $15,519 |
| 2026-02-09 | Pitofsky Jason | +1,000 | $492 | $492,000 |
| 2026-02-09 | RYAN ARTHUR F | -1 | $787.82 | $788 |
| 2026-02-09 | RYAN ARTHUR F | -2 | $786.29 | $1,573 |
| 2026-02-09 | RYAN ARTHUR F | -1 | $785.71 | $786 |
| 2026-02-09 | RYAN ARTHUR F | -1 | $784.59 | $785 |
| 2026-02-09 | RYAN ARTHUR F | -3 | $783.34 | $2,350 |
| 2026-02-09 | RYAN ARTHUR F | -1 | $782.53 | $783 |
| 2026-02-09 | RYAN ARTHUR F | -5 | $781.48 | $3,907 |
| 2026-02-09 | RYAN ARTHUR F | -1 | $780.09 | $780 |
| 2026-02-09 | RYAN ARTHUR F | -5 | $779.41 | $3,897 |
| 2026-02-09 | RYAN ARTHUR F | -12 | $778.53 | $9,342 |
| 2026-02-09 | RYAN ARTHUR F | -57 | $777.56 | $44,321 |
| 2026-02-09 | RYAN ARTHUR F | -10 | $776.59 | $7,766 |
| 2026-02-09 | RYAN ARTHUR F | -1 | $775.63 | $776 |
| 2026-01-07 | Bassler Bonnie L | -1,500 | - | - |
| 2026-01-07 | Bassler Bonnie L | -1,500 | $800 | $1,200,000 |
| 2026-01-07 | Bassler Bonnie L | +1,500 | $374.12 | $561,180 |
| 2026-01-02 | Guarini Kathryn | +1,962 | - | - |
| 2026-01-02 | Guarini Kathryn | +155 | - | - |
| 2026-01-02 | Bassler Bonnie L | +1,962 | - | - |
| 2026-01-02 | Bassler Bonnie L | +155 | - | - |
| 2026-01-02 | Zoghbi Huda Y | +1,962 | - | - |
| 2026-01-02 | Zoghbi Huda Y | +155 | - | - |
| 2026-01-02 | Schenkein David P | +1,962 | - | - |
| 2026-01-02 | Schenkein David P | +155 | - | - |
| 2026-01-02 | Thompson Craig B. | +1,962 | - | - |
| 2026-01-02 | Thompson Craig B. | +155 | - | - |
| 2026-01-02 | GOLDSTEIN JOSEPH L | +1,962 | - | - |
| 2026-01-02 | GOLDSTEIN JOSEPH L | +155 | - | - |
| 2026-01-02 | SING GEORGE L | +1,962 | - | - |
| 2026-01-02 | SING GEORGE L | +155 | - | - |
| 2026-01-02 | COLES N ANTHONY | +1,962 | - | - |
| 2026-01-02 | COLES N ANTHONY | +155 | - | - |
| 2026-01-02 | POON CHRISTINE A | +1,962 | - | - |
| 2026-01-02 | POON CHRISTINE A | +155 | - | - |
| 2026-01-02 | RYAN ARTHUR F | +1,962 | - | - |
| 2026-01-02 | RYAN ARTHUR F | +155 | - | - |
| 2026-01-02 | BROWN MICHAEL S | +1,962 | - | - |
| 2026-01-02 | BROWN MICHAEL S | +155 | - | - |
| 2025-12-31 | YANCOPOULOS GEORGE | -28,570 | - | - |
| 2025-12-31 | YANCOPOULOS GEORGE | -28,570 | $772.09 | $22,058,611 |
| 2025-12-31 | YANCOPOULOS GEORGE | +28,570 | - | - |
| 2025-12-31 | SCHLEIFER LEONARD S | -28,570 | - | - |
| 2025-12-31 | SCHLEIFER LEONARD S | -28,570 | $772.09 | $22,058,611 |
| 2025-12-31 | SCHLEIFER LEONARD S | +28,570 | - | - |
| 2025-12-30 | SING GEORGE L | -9,212 | - | - |
| 2025-12-30 | SING GEORGE L | -6,188 | $774.03 | $4,789,698 |
| 2025-12-30 | SING GEORGE L | +9,212 | $520.01 | $4,790,332 |
| 2025-12-09 | MURPHY ANDREW J | -4,229 | $701.51 | $2,966,686 |
| 2025-12-09 | McCourt Marion | -1,021 | $701.51 | $716,242 |
| 2025-12-09 | Van Plew Daniel P | -2,552 | $701.51 | $1,790,254 |
| 2025-12-09 | YANCOPOULOS GEORGE | -146,815 | - | - |
| 2025-12-09 | YANCOPOULOS GEORGE | -131,874 | $701.51 | $92,510,930 |
| 2025-12-09 | YANCOPOULOS GEORGE | +146,815 | $555.67 | $81,580,691 |
| 2025-12-09 | SCHLEIFER LEONARD S | -172,723 | - | - |
| 2025-12-09 | SCHLEIFER LEONARD S | -155,145 | $701.51 | $108,835,769 |
| 2025-12-09 | SCHLEIFER LEONARD S | +172,723 | $555.67 | $95,976,989 |
| 2025-12-08 | Pitofsky Jason | -989 | $712.94 | $705,098 |
| 2025-12-08 | MURPHY ANDREW J | -1,699 | $712.94 | $1,211,285 |
| 2025-12-08 | Fenimore Christopher R. | -992 | $712.94 | $707,236 |
| 2025-12-08 | McCourt Marion | -1,336 | $712.94 | $952,488 |
| 2025-12-08 | Van Plew Daniel P | -1,906 | $712.94 | $1,358,864 |
| 2025-12-08 | LAROSA JOSEPH J | -1,396 | $712.94 | $995,264 |
| 2025-12-05 | Pitofsky Jason | +2,261 | - | - |
| 2025-12-05 | Pitofsky Jason | +2,064 | - | - |
| 2025-12-05 | MURPHY ANDREW J | +18,315 | - | - |
| 2025-12-05 | MURPHY ANDREW J | +3,715 | - | - |
| 2025-12-05 | Fenimore Christopher R. | +14,924 | - | - |
| 2025-12-05 | Fenimore Christopher R. | +3,027 | - | - |
| 2025-12-05 | McCourt Marion | +12,210 | - | - |
| 2025-12-05 | McCourt Marion | +2,476 | - | - |
| 2025-12-05 | Van Plew Daniel P | +18,315 | - | - |
| 2025-12-05 | Van Plew Daniel P | +3,715 | - | - |
| 2025-12-05 | LAROSA JOSEPH J | +12,210 | - | - |
| 2025-12-05 | LAROSA JOSEPH J | +2,476 | - | - |
| 2025-11-20 | Bassler Bonnie L | -760 | - | - |
| 2025-11-20 | Bassler Bonnie L | -760 | $750 | $570,000 |
| 2025-11-20 | Bassler Bonnie L | +760 | $371.4 | $282,264 |
| 2025-11-20 | LAROSA JOSEPH J | -14,450 | - | - |
| 2025-11-20 | LAROSA JOSEPH J | -12,686 | $736.77 | $9,346,664 |
| 2025-11-20 | LAROSA JOSEPH J | +14,450 | $555.67 | $8,029,431 |
| 2025-11-07 | Pitofsky Jason | -431 | $651.43 | $280,766 |
| 2025-10-30 | MURPHY ANDREW J | -1,538 | - | - |
| 2025-10-30 | POON CHRISTINE A | -2,712 | - | - |
| 2025-10-30 | POON CHRISTINE A | +2,712 | $520.01 | $1,410,267 |
| 2025-10-29 | MURPHY ANDREW J | -35,000 | - | - |
| 2025-10-29 | MURPHY ANDREW J | -32,490 | $648.82 | $21,080,162 |
| 2025-10-29 | MURPHY ANDREW J | +35,000 | $555.67 | $19,448,450 |
| 2025-10-29 | POON CHRISTINE A | -6,500 | - | - |
| 2025-10-29 | POON CHRISTINE A | -388 | $657.29 | $255,029 |
| 2025-10-29 | POON CHRISTINE A | -712 | $656.5 | $467,428 |
| 2025-10-29 | POON CHRISTINE A | -100 | $655.1 | $65,510 |
| 2025-10-29 | POON CHRISTINE A | -1,915 | $654.42 | $1,253,214 |
| 2025-10-29 | POON CHRISTINE A | -2,735 | $653.5 | $1,787,323 |
| 2025-10-29 | POON CHRISTINE A | -650 | $652.68 | $424,242 |
| 2025-10-29 | POON CHRISTINE A | +6,500 | $520.01 | $3,380,065 |